DNL 747

Drug Profile

DNL 747

Alternative Names: DNL747

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard University
  • Developer Denali Therapeutics Inc
  • Class Antidementias; Small molecules
  • Mechanism of Action Receptor-interacting protein serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 19 Mar 2018 Denali Therapeutics has patent protection for RIPK1 inhibitors till 2037
  • 19 Mar 2018 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Netherlands (unspecified route)
  • 19 Mar 2018 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top